HIV Seropositivity Clinical Trial
— ParcoursHaitiOfficial title:
Precariousness and Sexual Vulnerability During the Life Course and Migration of People From Haiti Living With or Without HIV in French Guiana (PARCOURS D'HAÏTI)
French Guiana, a French territory located in South America, faces several social challenges including financial insecurity, unemployment and significant immigration. The degraded living conditions of migrants arriving in the territory are likely to put them in a situation of sexual vulnerability that could increase their risk of acquiring HIV (human immunodeficiency virus). This study proposes to conduct a survey of a group of people living with HIV in French Guiana who were born in Haiti and a group of Haitian people who are not HIV positive. With the help of interviewers who speak Haitian Creole, it will allow us to better understand the life paths of people from Haiti and their periods of vulnerability. Investigators will also focus on the use of testing and retention in care for those living with HIV. The results of this work will allow for the mobilization of resources and better adjustment of social support, prevention and care interventions implemented in French Guiana for migrant populations and/or those in precarious situations.
Status | Recruiting |
Enrollment | 784 |
Est. completion date | November 4, 2022 |
Est. primary completion date | May 4, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: For both groups, patient : - Born in Haiti, regardless of current nationality and date of arrival in France - Aged between 18 and 60 years' old - Arrived in French Guiana for more than 3 months - Not opposed to participating in the study For the HIV group - Living with HIV and diagnosed for more than 3 months, regardless of their status regarding hepatitis B and C - Be followed by one of the study's partner physicians in the hospitals of Cayenne, Kourou or Saint Laurent du Maroni For the non-HIV group - Declared not to be infected with HIV, regardless of their status with respect to hepatitis B and C - Being followed by one of the study's partner physicians or being recruited in the public space of one of the cities targeted by the study (Cayenne, Matoury, Rémire-Montjoly, Macouria, Kourou, Montsinery-Tonnegrande, Saint-Laurent-du-Maroni or Mana) Exclusion Criteria: - Unable to answer the interviewer in French or Haitian Creole - Persons under guardianship or trusteeship |
Country | Name | City | State |
---|---|---|---|
French Guiana | Centre Hospitalier de Cayenne | Cayenne | France |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier de Cayenne |
French Guiana,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of unsafe sex | Frequency of unsafe sex (including forced and paid sex) after arrival in French Guiana of people from Haiti and its association with their living conditions and acquisition of HIV infection | at inclusion | |
Secondary | the number of countries of residence | the number of countries of residence during the lifetime and the duration of residence in each country, as well as access to health coverage and first screening in years of increased migration from Haiti | at inclusion | |
Secondary | level of precariousness | type of housing | at inclusion | |
Secondary | level of precariousness | type of resources | at inclusion | |
Secondary | level of precariousness | right to stay | at inclusion | |
Secondary | level of precariousness | type of health coverage | at inclusion | |
Secondary | level of precariousness | use of HIV and HBV screening year after year after arrival in French Guiana | at inclusion | |
Secondary | delay between arrival in French Guiana and the first screening for sexually transmitted infections (STIs) and HIV diagnosis for positive persons | Identification of factors associated with earlier screening among the social indicators mentioned above | at inclusion | |
Secondary | Attendance at preventive medicine facilities | Attendance at preventive medicine facilities | at inclusion | |
Secondary | delay between diagnosis and entry into care. | Description of prolonged disruptions in care. Associated factors. | at inclusion | |
Secondary | number of partners | number of partners in the course of a lifetime and in the last twelve months, long relationships, occasional relationships, economic-sexual exchanges, forced relationships, recourse to paid sex year after year. | at inclusion | |
Secondary | description of clades of the Pol gene of the HIV genotyping sequence | list of clades of the Pol gene of the HIV genotyping sequence (Pol gene sequence) performed at the beginning of the care of participants living with HIV (phylogenetic analysis). | at inclusion | |
Secondary | birth control methods used | birth control methods used | at inclusion | |
Secondary | number of desired and unwanted pregnancies | number of desired and unwanted pregnancies | at inclusion | |
Secondary | number of voluntary termination of pregnancy | number of voluntary termination of pregnancy | at inclusion | |
Secondary | number of abandonment of care during the Covid-19 epidemic | number of abandonment of care during the Covid-19 epidemic | at inclusion | |
Secondary | number in break in follow-up and treatment during the Covid-19 epidemic | number in break in follow-up and treatment during the Covid-19 epidemic | at inclusion | |
Secondary | delay in care during the Covid-19 epidemic | delay in care during the Covid-19 epidemic | at inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03661203 -
Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
|
||
Completed |
NCT00381212 -
A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05983536 -
The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
|
||
Recruiting |
NCT04832477 -
Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US
|
N/A | |
Active, not recruiting |
NCT04044586 -
HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
|
||
Completed |
NCT03218839 -
Evaluation of the PrePex Device for Rapid Scale-up of VMMC, Phase 3 Field Implementation Trial With HIV + Adult Males
|
N/A | |
Active, not recruiting |
NCT00797030 -
Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus
|
Phase 4 | |
Recruiting |
NCT04088916 -
Proviral DNA as a Target for HIV-1 Resistance Analysis
|
||
Completed |
NCT03367130 -
Improving Clinic Attendance for Medication Collection Among HIV Positive Individuals in Nepal
|
N/A | |
Completed |
NCT04849767 -
National Survey About Trajectory and Life Conditions of HIV Trans People in France
|
||
Completed |
NCT05674682 -
Seroincidence Study Among Men Who Have Sex With Men and Transgender Women - The ImPrEP Seroincidence Study
|
N/A | |
Completed |
NCT00130819 -
Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants
|
Phase 2 | |
Active, not recruiting |
NCT04706624 -
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
|
N/A | |
Recruiting |
NCT03858478 -
Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST
|
Phase 4 | |
Completed |
NCT02154971 -
Assessment of Age-related Hearing Loss in HIV-1 Patients
|
||
Recruiting |
NCT03311945 -
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
|
Phase 3 | |
Recruiting |
NCT03333083 -
Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen
|
Phase 3 | |
Recruiting |
NCT03795415 -
ANRS12373 GUNDO SO - Evaluation of an Empowerment Program for WLHIV in Mali
|
||
Completed |
NCT02003989 -
Revealing Increased Axonal Loss in Treated HIV Patients
|
N/A | |
Completed |
NCT01813292 -
Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV Patients Treated With Tenofovir +/- Emtricitabine
|
N/A |